Chimerix Dirección

Dirección controles de criterios 2/4

El CEO de Chimerix es Mike Andriole , nombrado en Aug 2023, tiene una permanencia de 1.25 años. compensación anual total es $1.31M, compuesta por 40.3% salario y 59.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.37% de las acciones de la empresa, por valor de €285.92K. La antigüedad media del equipo directivo y de la junta directiva es de 1.2 años y 5.6 años, respectivamente.

Información clave

Mike Andriole

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO	40.3%
Permanencia del CEO	1.3yrs
Participación del CEO	0.4%
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	5.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mike Andriole en comparación con los beneficios de Chimerix?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$84m
Jun 30 2024	n/a	n/a	-US$85m
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$1m	US$528k	-US$82m
Sep 30 2023	n/a	n/a	-US$85m
Jun 30 2023	n/a	n/a	US$180m
Mar 31 2023	n/a	n/a	US$176m
Dec 31 2022	US$2m	US$455k	US$172m
Sep 30 2022	n/a	n/a	US$154m
Jun 30 2022	n/a	n/a	-US$106m
Mar 31 2022	n/a	n/a	-US$101m
Dec 31 2021	US$2m	US$433k	-US$173m
Sep 30 2021	n/a	n/a	-US$145m
Jun 30 2021	n/a	n/a	-US$138m
Mar 31 2021	n/a	n/a	-US$131m
Dec 31 2020	US$960k	US$420k	-US$44m
Sep 30 2020	n/a	n/a	-US$35m
Jun 30 2020	n/a	n/a	-US$98m
Mar 31 2020	n/a	n/a	-US$105m
Dec 31 2019	US$1m	US$292k	-US$113m

Compensación vs. Mercado: La compensación total de Mike($USD1.31M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD472.15K).

Compensación vs. Ingresos: La compensación de Mike ha sido consistente con los resultados de la empresa en el último año.

CEO

Mike Andriole (51 yo)

1.3yrs

Permanencia

US$1,312,421

Compensación

Mr. Michael T. Andriole, also known as Mike, is CEO, President & Director of Chimerix, Inc. since August 01, 2023 and had been the Chief Business Officer of Chimerix, Inc. since April 8, 2019 until August...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Andriole	CEO, President & Director	1.3yrs	US$1.31m	0.37% € 285.9k
Michael Alrutz	Senior VP	10.2yrs	US$793.85k	0.15% € 112.9k
Allen Melemed	Chief Medical Officer	4.4yrs	US$931.79k	0.062% € 47.2k
Michelle LaSpaluto	Chief Financial Officer	less than a year	sin datos	0.12% € 94.5k
Thomas Riga	Chief Operating & Commercial Officer	less than a year	sin datos	sin datos
David Jakeman	Vice President of Accounting & Finance	5.4yrs	sin datos	0.12% € 93.6k
Joshua Allen	Chief Scientific Officer	less than a year	sin datos	sin datos
Roy Ware	Chief Manufacturing Technology Officer	1.1yrs	sin datos	sin datos

1.2yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CXF no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Andriole	CEO, President & Director	1.3yrs	US$1.31m	0.37% € 285.9k
Fred Middleton	Independent Director	6.7yrs	US$119.52k	0.34% € 261.8k
Seth Rudnick	Member of Scientific Advisory Board	no data	sin datos	sin datos
Martha Demski	Lead Independent Director	19.8yrs	US$144.52k	0.080% € 61.3k
Michael Sherman	Chairman	5.6yrs	US$1.52m	0.39% € 301.1k
Douglas Richman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Pratik Multani	Independent Director	4.8yrs	US$104.52k	0% € 0
Michael Boeckh	Member of Clinical Advisory Board	no data	sin datos	sin datos
Earl Kern	Member of Scientific Advisory Board	no data	sin datos	sin datos
Raymund Razonable	Member of Clinical Advisory Board	no data	sin datos	sin datos
Robert Meyer	Independent Director	6.7yrs	US$117.02k	0.039% € 29.9k
Victoria Vakiener	Independent Director	3.6yrs	US$107.02k	0% € 0

5.6yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de CXF se considera experimentada (5.6 años de antigüedad promedio).

Chimerix Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Recent updates

Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 3Q 2023)

Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2023)

Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings released: US$0.93 loss per share (vs US$1.97 profit in FY 2022)

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2022)

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought €90k worth of stock

First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2022)

Full year 2022 earnings released: EPS: US$1.97 (vs US$2.04 loss in FY 2021)

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings released: EPS: US$2.75 (vs US$0.21 loss in 3Q 2021)

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Forecast to breakeven in 2022

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.21 loss in 2Q 2021)

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

First quarter 2022 earnings released: US$0.28 loss per share (vs US$1.22 loss in 1Q 2021)

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research

Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)

Forecast to breakeven in 2023

Independent Director recently bought €65k worth of stock

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$1.22 loss per share (vs US$0.17 loss in 1Q 2020)

Full year 2020 earnings released: US$0.70 loss per share (vs US$2.03 loss in FY 2019)

Revenue misses expectations

Chimerix, Inc. Reports Topline Results from the First Cohort of Its Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study

New 90-day high: €8.81

New 90-day high: €7.91

Chimerix, Inc. (NasdaqGM:CMRX) acquired Oncoceutics, Inc. from Spring Mountain Capital, LP and others for $68.3 million

New 90-day high: €6.58

New 90-day high: €3.46

New 90-day high: €2.58

Revenue beats expectations

Third quarter 2020 earnings released: US$0.18 loss per share

Chimerix, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €1.93

New 90-day low - €2.22

New 90-day low - €2.47

First half earnings released

Chimerix, Inc. to Report Q2, 2020 Results on Aug 10, 2020